Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Net Income (2016 - 2025)

Spero Therapeutics' Net Income history spans 10 years, with the latest figure at $31.5 million for Q4 2025.

  • For Q4 2025, Net Income rose 301.9% year-over-year to $31.5 million; the TTM value through Dec 2025 reached $8.6 million, up 113.42%, while the annual FY2025 figure was $8.6 million, 113.42% up from the prior year.
  • Net Income reached $31.5 million in Q4 2025 per SPRO's latest filing, up from -$7.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $52.2 million in Q4 2023 to a low of -$30.1 million in Q1 2022.
  • Average Net Income over 5 years is -$7.7 million, with a median of -$13.6 million recorded in 2023.
  • Peak YoY movement for Net Income: tumbled 454.02% in 2024, then soared 301.9% in 2025.
  • A 5-year view of Net Income shows it stood at -$27.4 million in 2021, then surged by 215.6% to $31.7 million in 2022, then surged by 64.76% to $52.2 million in 2023, then plummeted by 129.89% to -$15.6 million in 2024, then soared by 301.9% to $31.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Net Income are $31.5 million (Q4 2025), -$7.4 million (Q3 2025), and -$1.7 million (Q2 2025).